Adequate infusion rate of remimazolam for induction of general anesthesia in adult patients

Not Applicable

Completed

• Conditions: Not Applicable

• Registration Number: KCT0006805
• Lead Sponsor: Samsung Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2022-01-28
• Last Update Posted: 20 September 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

1) ASA class I - III
2) Age between 19 to 65
2) Patient who has elective surgery under general anesthesia

Exclusion Criteria

1) Children (under 18 years old)
2) BMI>30kg/m2 or <18.5kg/m2
3) People with severe liver disease
4) Neuromuscular disease or mental illness
5) metabolic disease
6) drug or alcohol addiction
7) Emergency surgery
8) Pregnant women, lactating women
9) Those who are contraindicated in benzodiazepine drugs and sevoflurane (e.g., patients who are allergic to drugs or have a history of hypersensitivity reactions)
10) Patients with acute narrow-angle glaucoma
11) Patients in shock or coma
12) Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, and glucose-galactose malabsorption
13) Patients with severe hypersensitivity to dextran 40
14) If patient's anesthesiologist refuses to use remimazolam
15) Patients with sleep apnea syndrome
16) Patients with severe or acute respiratory failure

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
oss of consciousness within 2 minutes after injection of remimazolam

Secondary Outcome Measures

Name	Time	Method
blood pressure;heart rate;bispectral index;adverse effects (Tachycardia, bradycardia, hypertension, hypotension, hypoventilation, decrease of SpO2);total dose of remimazolam;Whether arousal or recall during surgery (using Modified Brice questionnaire)